A genetic predisposition has been identified in 30% of idiopathic pulmonary fibrosis (IPF) cases. Although it is highly probable that the genotype affects the disease susceptibility and course in almost all patients, the specific genotype goes undetected. The aim of the present study was to explore the effects of variants of the genes encoding interleukin-4 (IL-4), mucin 5B (MUC5B), toll interacting protein (TOLLIP), surfactant protein A (SFPTA), transforming growth factor-β (TGF-β) and transporters associated with antigen processing (TAP1 and TAP2) on the course of IPF. A total of 50 patients with IPF were enrolled, and variants of these genes were assessed. Lung function at the time of diagnosis and after 6, 12 and 18 months, and the number of acute exacerbations and deaths in each observation period were measured. ANOVA was used to test the association between gene polymorphisms and the decrease in lung function. There was no significant effect of the gene polymorphisms on the outcomes of patients up to 6 months during the observation period. After 12 months, an effect of an IL-4 single nucleotide polymorphism (SNP) (rs 2070874) on patient outcomes was observed [relative risk (RR) for T allele: 5.6; 95% confidence interval (CI), 0.79-39.0; P=0.053]. The RR of progression in patients with the IL-4 SNP (rs 2243250) and the CT and TT genotypes was 4.3 (95% CI, 1.1-17.5; P=0.046). A total of 18 months after the diagnosis of IPF, an effect of the TOLLIP polymorphism on patient outcome was detected (rs 111521887; risk allele GC; RR: 7.2; 95% CI, 0.97-53.6; P=0.052). Thus, IL-4 and TOLLIP gene polymorphisms may represent disease course-modifying factors, but not drivers of IPF.

Department of Biostatistics Institute of Clinical and Experimental Medicine 140 00 Prague Czech Republic

Department of Pathological Physiology Faculty of Medicine and Dentistry Palacky University 775 15 Olomouc Czech Republic

Department of Respiratory Medicine 1st Medical Faculty of Charles University and Thomayer University Hospital 140 00 Prague Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University 775 15 Olomouc Czech Republic

Zobrazit více v PubMed

Michalski JE, Schwartz DA. Genetic risk factors for idiopathic pulmonary fibrosis: Insights into immunopathogenesis. J Inflamm Res. 2021;13:1305–1318. doi: 10.2147/JIR.S280958. PubMed DOI PMC

Churg A. Centrilobular fibrosis in fibrotic (Chronic) hypersensitivity pneumonitis, usual interstitial pneumonia, and connective tissue disease-associated interstitial lung disease. Arch Pathol Lab Med. 2020;144:1509–1516. doi: 10.5858/arpa.2019-0628-RA. PubMed DOI

Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: Causes, diagnosis, clinical features, and treatments. J Clin Med. 2020;9(1081) doi: 10.3390/jcm9041081. PubMed DOI PMC

Meyer KC. Pulmonary fibrosis, part I: Epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. 2017;11:343–359. doi: 10.1080/17476348.2017.1312346. PubMed DOI

Ballester B, Milara J, Cortijo J. Mucins as a new frontier in pulmonary fibrosis. J Clin Med. 2019;8(1447) doi: 10.3390/jcm8091447. PubMed DOI PMC

Stock CJW, Renzoni EA. Telomeres in interstitial lung disease. J Clin Med. 2021;10(1384) doi: 10.3390/jcm10071384. PubMed DOI PMC

Snijder J, Peraza J, Padilla M, Capaccione K, Salvatore MM. Pulmonary fibrosis: A disease of alveolar collapse and collagen deposition. Expert Rev Respir Med. 2019;13:615–619. doi: 10.1080/17476348.2019.1623028. PubMed DOI

Schwartz DA. Idiopathic pulmonary fibrosis is a genetic disease involving mucus and the peripheral airways. Ann Am Thorac Soc. 2018;15 (Suppl):S192–S197. doi: 10.1513/AnnalsATS.201802-144AW. PubMed DOI PMC

Barros A, Oldham J, Noth I. Genetics of idiopathic pulmonary fibrosis. Am J Med Sci. 2019;357:379–383. doi: 10.1016/j.amjms.2019.02.009. PubMed DOI PMC

Walters GI. Occupational exposures and idiopathic pulmonary fibrosis. Curr Opin Allergy Clin Immunol. 2020;20:103–111. doi: 10.1097/ACI.0000000000000610. PubMed DOI

Zhang L, Ikegami M, Korfhagen TR, McCormack FX, Yoshida M, Senior RM, Shipley JM, Shapiro SD, Whitsett JA. Neither SP-A nor NH2-terminal domains of SP-A can substitute SP-D in regulation of alveolar homeostasis. Am J Physiol Lung Cell Mol Physiol. 2006;291:L181–L190. doi: 10.1152/ajplung.00015.2006. PubMed DOI

Froidure A, Marchal-Duval E, Homps-Legrand M, Ghanem M, Justet A, Crestani B, Milleux C. Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis. Eur Respir Rev. 2020;29(190140) doi: 10.1183/16000617.0140-2019. PubMed DOI PMC

Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. Lancet Respir Med. 2013;1:309–317. doi: 10.1016/S2213-2600(13)70045-6. PubMed DOI PMC

Aquino-Galvez A, Camarena A, Montaño M, Juarez A, Zamora AC, González-Avila G, Checa M, Sandoval-López G, Vargas-Alarcon G, Granados J, et al. Transporter associated with antigen processing (TAP) 1 gene polymorphisms in patients with hypersensitivity pneumonitis. Exp Mol Pathol. 2008;84:173–177. doi: 10.1016/j.yexmp.2008.01.002. PubMed DOI

Hanalioglu D, Ayvaz DC, Ozgur TT, van der Burg M, Sanal O, Tezcan I. A novel mutation in TAP1 gene leading to MHC class I deficiency: Report of two cases and review of the literature. Clin Immunol. 2017;178:74–78. doi: 10.1016/j.clim.2017.01.011. PubMed DOI

1000 Genome Project: https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes, visited on 14-Mar-2020.

Cho YA, Kim J. Association of IL4, IL13, and IL4R polymorphisms with gastrointestinal cancer risk: A meta-analysis. J Epidemiol. 2017;27:215–220. doi: 10.1016/j.je.2016.06.002. PubMed DOI PMC

Yoshimoto T. The hunt for the source of primary interleukin-4: How we discovered that natural killer T cells and basophils determine T helper type 2 cell differentiation in vivo. Front Immunol. 2018;9(716) doi: 10.3389/fimmu.2018.00716. PubMed DOI PMC

Gieseck RL III, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62–76. doi: 10.1038/nri.2017.90. PubMed DOI

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SV, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68. doi: 10.1164/rccm.201807-1255ST. PubMed DOI

Kocova E, Vanasek J, Koblizek V, Novosad J, Elias P, Bartos V, Sterclova M. Scoring of the radiological picture of idiopathic interstitial pneumonia: A study to verify the reliability of the method. Acta Radiol Open. 2015;4(2058460115605865) doi: 10.1177/2058460115605865. PubMed DOI PMC

Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–735. doi: 10.1183/09031936.05.00034905. PubMed DOI

Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968. doi: 10.1183/09031936.05.00035205. PubMed DOI

Wuyts WA, Wijsenbeek M, Bondue B, Bouros D, Bresser P, Robalo Cordeiro C, Hilberg O, Magnusson J, Manali ED, Morais A, et al. Idiopathic pulmonary fibrosis: Best practice in monitoring and managing a relentless fibrotic disease. Respiration. 2020;99:73–82. doi: 10.1159/000504763. PubMed DOI PMC

Vasakova M, Sterclova M, Matej R, Olejar T, Kolesar L, Skibova J, Striz I. IL-4 polymorphisms, HRCT score and lung tissue markers in idiopathic pulmonary fibrosis. Hum Immunol. 2013;74:1346–1351. doi: 10.1016/j.humimm.2013.07.011. PubMed DOI

Kishore A, Žižková V, Kocourková L, Petřek M. A dataset of 26 candidate gene and pro-inflammatory cytokine variants for association studies in idiopathic pulmonary fibrosis: Frequency distribution in normal Czech population. Front Immunol. 2015;6(476) doi: 10.3389/fimmu.2015.00476. PubMed DOI PMC

Sikorova K, Kishore A, Rapti A, Adam K, Kocourkova L, Zizkova V, Charikiopoulou M, Kalianos A, Bouros E, Bouros D, Petrek M. Association of TGF-β3 and ANXA11 with pulmonary sarcoidosis in Greek population. Expert Rev Respir Med. 2020;14:1065–1069. doi: 10.1080/17476348.2020.1784729. PubMed DOI

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–75. doi: 10.1164/rccm.201604-0801CI. PubMed DOI

Taha N, D'Amato D, Hosein K, Ranalli T, Sergiacomi G, Zompatori M, Mura M. Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: Are we following the right parameters? Respir Res. 2020;21(119) doi: 10.1186/s12931-020-01371-7. PubMed DOI PMC

Nathan N, Giraud V, Picard C, Nunes H, Dastot-Le Moal F, Copin B, Galeron L, De Ligniville A, Kuziner N, Reynaud-Gaubert M, et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet. 2016;25:1457–1467. doi: 10.1093/hmg/ddw014. PubMed DOI

Deng Y, Li Z, Liu J, Wang Z, Cao Y, Mou Y, Fu B, Mo B, Wei J, Cheng Z, et al. Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis. Hum Mutat. 2018;39:1238–1245. doi: 10.1002/humu.23566. PubMed DOI

Juarez I, Gutierrez A, Vaquero-Yuste C, Molanes-López EM, López A, Lasa I, Gómez R, Martin-Villa JM. TGFB1 polymorphisms and TGF-β1 plasma levels identify gastric adenocarcinoma patients with lower survival rate and disseminated disease. J Cell Mol Med. 2021;25:774–783. doi: 10.1111/jcmm.16131. PubMed DOI PMC

Zhu L, Wang L, Luo X, Zhang Y, Ding Q, Jiang X, Wang X, Pan Y, Chen Y. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-β signaling pathway. J Biol Chem. 2012;287:39653–3963. doi: 10.1074/jbc.M112.388009. PubMed DOI PMC

Kaur A, Mathai SM, Schwartz DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med (Lausanne) 2017;4(154) doi: 10.3389/fmed.2017.00154. PubMed DOI PMC

Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol. 2000;121:173–178. doi: 10.1046/j.1365-2249.2000.01264.x. PubMed DOI PMC

Qiu B, Huang B, Wang X, Liang J, Feng J, Chang Y, Li D. Association of TAP1 and TAP2 polymorphisms with the outcome of persistent HBV infection in a northeast Han Chinese population. Scand J Gastroenterol. 2012;47:1368–1374. doi: 10.3109/00365521.2012.725090. PubMed DOI

Biondini D, Cocconcelli E, Bernardinello N, Lorenzoni G, Rigobello C, Lococo S, Castelli G, Baraldo S, Cosio MG, Gregori D, et al. Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. Respir Res. 2021;22(98) doi: 10.1186/s12931-021-01694-z. PubMed DOI PMC

Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232–2239. doi: 10.1001/jama.2013.5827. PubMed DOI PMC

Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503–1512. doi: 10.1056/NEJMoa1013660. PubMed DOI PMC

Jiang H, Hu Y, Shang L, Li Y, Yang L, Chen Y. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. Int J Clin Exp Pathol. 2015;8:14953–14958. PubMed PMC

Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:906–913. doi: 10.1164/rccm.201403-0541OC. PubMed DOI PMC

Luzina IG, Lockatell V, Todd NW, Highsmith K, Keegan AD, Hasday JD, Atamas SP. Alternatively spliced variants of interleukin-4 promote inflammation differentially. J Leukoc Biol. 2011;89:763–770. doi: 10.1189/jlb.0510271. PubMed DOI PMC

Luzina IG, Keegan AD, Heller NM, Rook GA, Shea-Donohue T, Atamas SP. Regulation of inflammation by interleukin-4: A review of ‘alternatives’. J Leukoc Biol. 2012;92:753–764. doi: 10.1189/jlb.0412214. PubMed DOI PMC

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: A candidate gene sequencing study. Lancet Respir Med. 2018;6:603–614. doi: 10.1016/S2213-2600(18)30135-8. PubMed DOI PMC

Huang Y, Ma SF, Vij R, Oldham JM, Herazo-Maya J, Broderick SM, Strek ME, White RW, Hogarth DK, Sandbo NK, et al. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15(147) doi: 10.1186/s12890-015-0142-8. PubMed DOI PMC